Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107


Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer.

Ogiya R, Sagara Y, Niikura N, Freedman RA.

Clin Breast Cancer. 2019 Jun;19(3):200-207.e1. doi: 10.1016/j.clbc.2019.01.005. Epub 2019 Jan 29.


Racial differences in outcomes for patients with metastatic breast cancer by disease subtype.

Vaz-Luis I, Lin NU, Keating NL, Barry WT, Lii H, Winer EP, Freedman RA.

Breast Cancer Res Treat. 2015 Jun;151(3):697-707. doi: 10.1007/s10549-015-3432-1. Epub 2015 May 29.


De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.

Press DJ, Miller ME, Liederbach E, Yao K, Huo D.

Clin Exp Metastasis. 2017 Dec;34(8):457-465. doi: 10.1007/s10585-017-9871-9. Epub 2017 Dec 29.


Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.

Schroeder MC, Rastogi P, Geyer CE Jr, Miller LD, Thomas A.

Oncologist. 2018 Apr;23(4):481-488. doi: 10.1634/theoncologist.2017-0398. Epub 2018 Jan 12.


Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population.

Tao L, Chu L, Wang LI, Moy L, Brammer M, Song C, Green M, Kurian AW, Gomez SL, Clarke CA.

Cancer Causes Control. 2016 Sep;27(9):1127-38. doi: 10.1007/s10552-016-0791-9. Epub 2016 Aug 5.


Differences in Breast Cancer Survival by Molecular Subtypes in the United States.

Howlader N, Cronin KA, Kurian AW, Andridge R.

Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):619-626. doi: 10.1158/1055-9965.EPI-17-0627. Epub 2018 Mar 28.


Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.

Wong Y, Raghavendra AS, Hatzis C, Irizarry JP, Vega T, Horowitz N, Barcenas CH, Chavez-MacGregor M, Valero V, Tripathy D, Pusztai L, Murthy RK.

Oncologist. 2019 Mar;24(3):313-318. doi: 10.1634/theoncologist.2018-0213. Epub 2018 Aug 23.


Prognostic significance of tumor subtypes in male breast cancer: a population-based study.

Leone JP, Leone J, Zwenger AO, Iturbe J, Vallejo CT, Leone BA.

Breast Cancer Res Treat. 2015 Aug;152(3):601-9. doi: 10.1007/s10549-015-3488-y. Epub 2015 Jul 1.


Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.

Prat A, Cheang MC, Galván P, Nuciforo P, Paré L, Adamo B, Muñoz M, Viladot M, Press MF, Gagnon R, Ellis C, Johnston S.

JAMA Oncol. 2016 Oct 1;2(10):1287-1294. doi: 10.1001/jamaoncol.2016.0922.


Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.

Liu J, Chen K, Jiang W, Mao K, Li S, Kim MJ, Liu Q, Jacobs LK.

J Cancer Res Clin Oncol. 2017 Jan;143(1):161-168. doi: 10.1007/s00432-016-2281-6. Epub 2016 Oct 4.


Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.

Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-MacGregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT.

Ann Oncol. 2014 Feb;25(2):384-91. doi: 10.1093/annonc/mdt525. Epub 2013 Dec 18.


Prognostic Significance of Tumor Subtypes in Women With Breast Cancer According to Stage: A Population-based Study.

Leone JP, Leone J, Zwenger AO, Vallejo CT, Leone BA.

Am J Clin Oncol. 2019 Jul;42(7):588-595. doi: 10.1097/COC.0000000000000563.


Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.

Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Borm GF, Tjan-Heijnen VC.

Breast Cancer Res Treat. 2013 Oct;141(3):507-14. doi: 10.1007/s10549-013-2711-y. Epub 2013 Oct 9.


Breast cancer-specific survival by age: Worse outcomes for the oldest patients.

Freedman RA, Keating NL, Lin NU, Winer EP, Vaz-Luis I, Lii J, Exman P, Barry WT.

Cancer. 2018 May 15;124(10):2184-2191. doi: 10.1002/cncr.31308. Epub 2018 Mar 2.


Breast Cancer Subtype as a Predictor of Lymph Node Metastasis according to the SEER Registry.

Mattes MD, Bhatia JK, Metzger D, Ashamalla H, Katsoulakis E.

J Breast Cancer. 2015 Jun;18(2):143-8. doi: 10.4048/jbc.2015.18.2.143. Epub 2015 Jun 26.


Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.

Rossi V, Nolè F, Redana S, Adamoli L, Martinello R, Aurilio G, Verri E, Sapino A, Viale G, Aglietta M, Montemurro F.

Breast. 2014 Feb;23(1):44-9. doi: 10.1016/j.breast.2013.10.005. Epub 2013 Nov 7.


Locoregional therapy in luminal-like and HER2-enriched patients with de novo stage IV breast cancer.

Chen PY, Cheng SH, Hung CF, Yu BL, Chen CM.

Springerplus. 2013 Nov 1;2:589. doi: 10.1186/2193-1801-2-589. eCollection 2013.


Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.

Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP, Weeks JC.

Cancer. 2012 Nov 15;118(22):5463-72. doi: 10.1002/cncr.27581. Epub 2012 Apr 27.


Impact of Breast Cancer Subtype Defined by Immunohistochemistry Hormone Receptor and HER2 Status on the Incidence of Immediate Postmastectomy Reconstruction.

Wu W, Cheng S, Deng H, Wu J, Mao K, Cao M.

Medicine (Baltimore). 2016 Jan;95(3):e2547. doi: 10.1097/MD.0000000000002547.


Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.

Leone JP, Leone J, Zwenger AO, Iturbe J, Leone BA, Vallejo CT.

Eur J Cancer. 2017 Mar;74:17-25. doi: 10.1016/j.ejca.2016.12.015. Epub 2017 Feb 6.


Supplemental Content

Support Center